Volume 16, Issue 5, May 2019 - First Report Managed Care
05/17/2019
The Senate Finance Committee recently examined the complicated role pharmacy benefit managers play in the pricing of pharmaceuticals. Six prominent themes emerged. First Report Managed Care consulted with a panel of experts to assess the...
The Senate Finance Committee recently examined the complicated role pharmacy benefit managers play in the pricing of pharmaceuticals. Six prominent themes emerged. First Report Managed Care consulted with a panel of experts to assess the...
The Senate Finance Committee...
05/17/2019
First Report Managed Care
News
Conference Insider
05/17/2019
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis.
Researchers recently found that patient-reported outcomes (PROs) were no different among patients treated with calcitonin gene-related peptide (CGRP) antagonists or onabotulinumtoxinA (ONA) for the indication of chronic migraine prophylaxis.
Researchers recently found that...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
Results from a randomized phase 2 trial presented at the Society for Gynecologic Oncology’s 50th Annual Meeting show that a newly developed immunotherapy treatment combined with standard chemotherapy improve the prognosis for patients with...
Results from a randomized phase 2 trial presented at the Society for Gynecologic Oncology’s 50th Annual Meeting show that a newly developed immunotherapy treatment combined with standard chemotherapy improve the prognosis for patients with...
Results from a randomized phase...
05/17/2019
First Report Managed Care
Department
Conference Insider
05/17/2019
Melissa Andel, MPP, vice president of health policy at Applied Policy and First Report Managed Care advisory board member, provided insight on progress made in relation to the Trump administration’s May 2018 blueprint to lower drug prices and...
Melissa Andel, MPP, vice president of health policy at Applied Policy and First Report Managed Care advisory board member, provided insight on progress made in relation to the Trump administration’s May 2018 blueprint to lower drug prices and...
Melissa Andel, MPP, vice...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
When patients received abuse-deterrent formulation (ADF) opioids, lower rates of opioid abuse, health care utilization, and medical costs were reported, according to recent analysis findings. The findings were presented at the AMCP Managed...
When patients received abuse-deterrent formulation (ADF) opioids, lower rates of opioid abuse, health care utilization, and medical costs were reported, according to recent analysis findings. The findings were presented at the AMCP Managed...
When patients received...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
A newly developed program, known as the Chronic Pain Program, was created as a multidisciplinary care management and coaching program that provides support and resources to patients with chronic pain. According to a team of researchers that...
A newly developed program, known as the Chronic Pain Program, was created as a multidisciplinary care management and coaching program that provides support and resources to patients with chronic pain. According to a team of researchers that...
A newly developed program, known...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
Within the health care decision-making process, the impact of patient-reported outcomes (PRO) and clinical outcome assessments (COAs) on payers is often low, despite efforts to include the patient voice, according to recent survey results...
Within the health care decision-making process, the impact of patient-reported outcomes (PRO) and clinical outcome assessments (COAs) on payers is often low, despite efforts to include the patient voice, according to recent survey results...
Within the health care...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
Within an integrated health care system, a pharmacist-managed deprescribing program, which focused on select antidiabetics among older patients with well-controlled type 2 diabetes, resulted in sustained benefit after one year in reducing the...
Within an integrated health care system, a pharmacist-managed deprescribing program, which focused on select antidiabetics among older patients with well-controlled type 2 diabetes, resulted in sustained benefit after one year in reducing the...
Within an integrated health care...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
Human papillomavirus (HPV) vaccination rates in Alabama counties correlate with the highest incident rates of HPV-related cancer, according to data presented at the Society for Gynecologic Oncology’s 50th Annual Meeting.
Human papillomavirus (HPV) vaccination rates in Alabama counties correlate with the highest incident rates of HPV-related cancer, according to data presented at the Society for Gynecologic Oncology’s 50th Annual Meeting.
Human papillomavirus (HPV)...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
Results from a randomized phase 2 trial presented at the Society for Gynecologic Oncology’s 50th Annual Meeting show that a newly developed immunotherapy treatment combined with standard chemotherapy improve the prognosis for patients with...
Results from a randomized phase 2 trial presented at the Society for Gynecologic Oncology’s 50th Annual Meeting show that a newly developed immunotherapy treatment combined with standard chemotherapy improve the prognosis for patients with...
Results from a randomized phase...
05/17/2019
First Report Managed Care
Conference Insider
05/17/2019
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
According to research presented...
05/17/2019
First Report Managed Care
